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 NEWS CELL CyCLE NEWS & viEWS
Cellular plasticity enables profound changes 
in cell phenotypes governed by tightly orches-
trated interplay among distinct functional 
classes of regulatory molecules. This process 
typically involves the control of specific gene 
expression programs with distinct functional 
impacts on cellular behavior. One such mani-
festation of remarkable cellular plasticity — 
epithelial-mesenchymal transition (EMT) — has 
recently attracted broad interest in the field 
of cancer research, nearly 30 years after the 
pioneering work by Elizabeth Hay.1 EMT is 
a cell phenotype conversion utilized in tis-
sue remodeling during embryonic develop-
ment, re-enacted in adult tissue homeostasis 
(e.g. during regeneration upon injury) and in 
pathological conditions such as development 
of invasive and metastatic carcinomas or in 
fibrotic processes affecting vital organs such 
as the kidney or lungs.2,3 Cancer EMT has been 
recently demonstrated to generate breast car-
cinoma cancer stem-cells (CSCs) characterized 
by mesenchymal markers and by the capacity 
of self-renewal and of initiating secondary 
tumorigenesis.4 in addition, the process of EMT 
involves regulatory molecules (e.g., transcrip-
tion factors Snail, Slug) that confer resistance 
to therapeutic induction of cell death. 
in a previous issue of Cell Cycle features a 
review by Jonas Fuxe and colleagues, which 
summarizes the latest findings on select sig-
naling and transcriptional regulation of the 
overlapping EMT and CSC phenotypes. The 
authors focus on the cross-talk between sig-
naling pathways that determine (or maintain) 
stem-cells and their niches and also direct the 
EMT process. The review elaborates on key 
pathways at the intersection of EMT and can-
cer: TGF-β/Smad, Wnt and Ras signaling. Next, 
the authors review the roles of numerous key 
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transcriptional regulators of EMT and of stem 
cell phenotype maintenance. Fuxe et al. build 
on the previous work on the Smad/cofactor 
complex roles in the target gene specific-
ity and the downstream activation/repression 
outcomes.5 The authors themselves signifi-
cantly contributed to this area of research by 
publishing an elegant study on the co-repres-
sor role of the SNAi1-SMAD3/4 complex in 
promoting TGF-β-directed cancer-related EMT 
via repression of key junctional proteins such 
as Coxsackie- and adenovirus receptor (CAR), 
occludin and E-cadherin.6 
in a previous issue of Cell Cycle, the authors 
review the fine-tuning roles of EMT-promoting 
Smad complexes (EPSCs) that involve many 
EMT-associated transcriptional regulators as 
cofactors of the Smad3/4 binding to regu-
latory chromatin regions — the transcription 
factors Snail, Zeb1/2, AP-1, β-catenin, LEF/TCF, 
Twist, Sp1 and chromatin structure regula-
tors p300, HDACs, HMGA2 and pCAF can be 
parts of the EPSCs and many of them are also 
linked to upstream signaling events associated 
with stem-cell phenotypes. The category of 
EPSCs is then further structured into subsets 
that provide essentially two types of down-
stream action — either repression of epithelial 
components or activation of mesenchymal 
markers, both essential for EMT. The review is 
concluded by insights on inflammatory com-
ponents within the tumor environment and 
their roles in EMT, and on tumor stem cell 
niches and the link between the degree of cell 
differentiation and invasive and metastatic 
properties of EMT-generated cancer stem cells.
Historically, the primary focus on EMT in 
cancer has been aimed at signaling pathways, 
transcriptional regulators and most recently 
on the roles of microRNAs.3 The future research 
directions will likely involve a broader, more 
comprehensive search for novel molecular 
regulators of the process, to define prospec-
tive targets for therapeutic interventions. The 
authors propose that new EPSC downstream 
of TGF-β signals need to be systematically 
identified, together with their roles in patho-
logical instances of EMT. indeed, the rapidly 
evolving high-throughput quantitative tech-
niques such as next-generation sequencing 
or quantitative proteomics have the capacity 
to generate catalogs of new EPSC compo-
nents and to determine the dynamics of their 
physical distribution on chromatin during EMT, 
together with chromatin structure changes. 
With these high-throughput quantitative 
tools, the aberrant post-transcriptional control 
of gene expression involving deregulation of 
microRNAs, mRNA processing and turnover 
(such as deregulation of differential splicing 
or of RNA nonsense-mediated decay) will also 
warrant close attention, together with abnor-
malities in post-translational protein modifica-
tions and in the process of protein turnover. 
The big picture of the nature and importance 
of the EMT regulators in tumorigenesis has 
been already rapidly emerging. The current 
review by Fuxe et al. is a very timely and 
focused summary of this exciting and impor-
tant area of research.
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Maintenance of genomic stability is funda-
mental for cells to survive to many rounds of 
division during their lifetime. To coordinate cell 
cycle events, surveillance mechanisms known 
as cell cycle checkpoints have evolved, ensur-
ing that replication and cell division occur 
correctly. The oncosuppressor p53 plays a 
crucial role in this process. Depending on 
the cellular context, transactivation of p53 
can stimulate cell cycle arrest in different cell 
cycle stages as well as apoptosis.1 it also has 
a crucial role in the G1 tetraploidy checkpoint 
by preventing the survival and propagation 
of tetraploid cells.2 Tetraploidy represents an 
important intermediate between diploidy and 
aneuploidy and is a common feature of human 
cancer. Therefore the molecular mechanisms 
through which tumor cells proceed from dip-
loid to aneuploid are extremely important in 
cancer research. Tetraploidy can arise when 
cells aberrantly exit from mitosis, after failure 
of spindle assembly, chromosome segregation 
or cytokinesis.3 The G1 arrest of tetraploid cells 
generated by spindle checkpoint failure or by 
failure of cytokinesis is p53 dependent through 
the induction of p21.2 it has been recently 
described that Chk1 inhibition, which causes 
spindle checkpoint defects and mitotic aber-
rations, induces a p53 dependent G1 tetraploid 
block.4, 5 The induction of tetraploid cell death 
triggered by inhibition of Chk1 requires p38α 
MAPK, which acts as a p53 kinase activated by 
Chk1 depletion.6 p38α MAPK is involved in the 
responses to a variety of stress agents regulat-
ing DNA damage repair, cell cycle arrest and 
apoptosis.7 in undamaged cell cycle p38α has 
a role in controlling the entry of cells in mito-
sis through negative regulation of Cdc25B.8 
p38α as an inducer of aneuploidy in p53-/- tetraploid cells
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The fact that p38 MAPK positively regulates 
several tumor suppressor (i.e., p53) pathways 
and attenuates oncogenic (i.e., Cdc25B phos-
phatase) signals assigns to this protein a role of 
oncosuppressor.7 in addition p38α, acting as a 
p53 kinase in Chk1 depleted tetraploid cells, is 
fundamental for blocking the re-replication of 
tetraploid cells, and plays an active part in the 
maintenance of genomic stability. However, 
vitale et al. describe a new role of p38α in con-
trolling proliferation of p53-/- tetraploid cells, in 
contrast with its function in preventing aneu-
ploidy and avoiding genomic instability.9 After 
having generated tetraploid clones from dip-
loid p53+/+ and p53-/- HCT-116 cells, they found 
that p53-/- tetraploid cells showed an increase 
in phosphorylation of p38α. They noted too 
that p38α hyperphosphorylation accumulates 
in mitotic tetraploid cells and behaves like 
a mitotic passenger protein by localizing in 
centrosomes in metaphase and in midbody 
in telophase. To understand the significance 
of phospho-p38α in mitotic progression, siR-
NAs or chemical agents were used to inhibit 
p38α in both p53+/+ and p53-/- tetraploid cells. 
There was a consistent effect in the cell cycle 
profile in p53-/- tetraploid cells; p38α inhibi-
tion resulted in a partial block in the G2/M 
phase associated with activation of the spindle 
assembly checkpoint, which raised the mitotic 
index and reduced the anaphase-telophase 
shift. p38α depletion increased monopolar 
and bipolar metaphases and reduced multi-
polar mitoses which were common among 
unstable p53-/- tetraploid cells, generating an 
aneuploid population (with a near to diploid 
DNA content). Taken together these results 
highlight that p38α is a major player in the 
mitotic progression of p53-/- tetraploid cells 
and indicate a novel function of p38α in the 
division of aneuploid cells. According to these 
data in a p53-/- background p38α would act as 
promoter of tetraploid cell division, inducing 
aneuploidy and genomic instability instead of 
preventing it. it would be interesting to inves-
tigate the pathway that in the p53-/- context 
is involved in the hyperphosphorylation of 
p38α, contributing to its oncogenic role. These 
authors in a recent paper showed that in the 
same p53-/- tetraploid cell system the onco-
gene MOS is upregulated and is required for 
multipolar division.10 MOS may therefore have 
a part in inhibiting centrosomes coalescence. 
As both MOS and phosphorylated p38α are 
more expressed in unstable p53-/- tetraploid 
cellular clones and can associate with centro-
somes, hypothetically the two proteins might 
reside in the same molecular pathway nega-
tively controlling the ability of supernumerary 
centrosomes to form clusters, thus increasing 
aneuploid cell division. Specifically in tumors 
with this molecular feature (p53-/- tetraploid) 
p38α may be considered as a target to inhibit 
to prevent aneuploidy.  
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Fighting of Casein kinase 1 and PP2A/Shugoshin for cohesins during meiosis I
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Meiosis is a specialized cell division that gener-
ates haploid gametes from diploid precursor 
cells. This is accomplished by two successive 
rounds of chromosome segregation (meiosis 
i and meiosis ii) after a single round of DNA 
replication. During prophase i, the homologs, 
each with two sister chromatids, pair and 
recombine to form chiasmate bivalents with 
four chromatids. in metaphase i bivalents, in 
spite of recombination, segments of sister 
chromatids remain tightly associated by mul-
tisubunit cohesin complexes at the arms, and 
also at centromeres (Fig. 1). Moreover, sister 
kinetochores must be closely associated to 
operate as a single functional unit per homo-
log and then permit the accurate biorientation 
of bivalents at the metaphase i plate (ref. 1). 
During the metaphase i/anaphase i transition, 
Excess dietary free fatty acids (FA) contribute 
substantially to obesity and linked metabolic 
disorders. Overload of the cellular lipid homeo-
static mechanisms that normally protect 
against excess FA leads to the accumulation 
of lipids in non-adipose tissues, culminating in 
cell dysfunction and death. This phenomenon, 
known as lipotoxicity, is believed to be a con-
tributing factor in the etiology of non-insulin 
dependent diabetes mellitus, cardiomyopathy 
and other obesity-mediated metabolic dis-
orders.1 Accumulating evidence points to a 
close relationship between perturbed lipid 
homeostasis and endogenous cell death pro-
grams, particularly apoptosis.1 An imbalance 
of mitochondrial cardiolipin, disruption of 
mitochondrial function, reactive oxygen spe-
cies (ROS) generation and endoplasmic reticu-
lum stress are among the frequently described 
pro-apoptotic effects attributed to saturated 
fatty acids (SFA) which are also precursors for 
the production of pro-apoptotic ceramides.2 
Monounsaturated (MUFA) and polyunsatured 
fatty acids (PUFA), although apparently not 
as cytotoxic as SFA in mammals, are also now 
recognized to be part of the repertoire of cel-
lular assassins.3 However, the multiple cellular 
mechanisms determining the FA-induced cell 
death process that depend both on the FA 
chain length and saturation remain largely 
unknown. 
The novel findings described by 
Rockenfeller and coworkers in a previous issue 
of Cell Cycle4 correlate the higher levels of PUFA 
present in common nutritional cooking oils 
with increasing sensitivity of wild type yeast 
Overeating yeast display fatty acid-induced necrotic cell death
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cells in the presence of lipases, which mimics 
the environment of the small intestine. Since 
the first reports on yeast apoptosis,5-7 yeast 
has been established as a powerful model to 
study the mechanisms and the phylogeneti-
cally conserved pathways of programmed cell 
death.8 it has been argued that free FA induces 
apoptosis in both mammalian cells and fission 
yeast,1,9 and it has been suggested to induce 
apoptosis in budding yeast as well.10 However, 
challenging the common belief that FA only 
elicit apoptosis, the results of this study estab-
lish that yeast cell death induced by FA is medi-
ated by a necrotic pathway that results in a 
high percentage of cells with reduced plasma 
membrane integrity and high ROS genera-
tion without phosphatidylserine exposition. 
Rockenfeller and coworkers strengthened 
these initial findings using a yeast quadru-
ple mutation (QKO) that genetically ablates 
the yeast neutral lipid biosynthetic pathway 
which, combined with the exogenous addi-
tion of unsaturated fatty acids (UFA), models 
acute lipotoxicity.10 The authors’ analysis of the 
effects of oleic (OA), linoleic (LA) and linolenic 
(L3A) acids on QKO mutant cells establishes 
a link between the degree of unsaturation of 
FA and the primary activation of a necrotic 
cell death program determined by annexinv/
propidium iodide staining and ROS produc-
tion. Their findings suggest that the level of 
FA saturation/unsaturation could be a crucial 
modulator of cell death mode and intensity. 
The necrotic cell death pathway triggered by 
UFA is shown to be dependent on mitochon-
dria and most importantly to be associated 
with the nuclear release of Nhp6Ap, the ortho-
log of HMGB1, which is a bona fide hallmark of 
necrotic cell death.8
in summary, taking advantage of the con-
servation of the regulatory processes relevant 
to establishing cell death and lipid homeo-
stasis in yeast, the authors provide important 
insights into the specific molecular mecha-
nisms leading to FA-induced cell death, which 
are still controversial. This study is important 
because it describes several new groundbreak-
ing insights into lipotoxicity. Not only has it 
highlighted the potential deleterious effects of 
PUFA, a major component of nutritional cook-
ing oils, on human health but it also challenges 
the dogma that lipotoxicity is always related 
to apoptosis by showing that common dietary 
UFA leads to a distinct cell death fate, necrosis. 
The discovery that FA induces necrosis will 
have potential clinical implications related to 
the pathophysiological effects of eliciting a 
pro-inflammatory response in the context of 
lipotoxicity. 
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the enzyme separase cleaves the meiosis-
specific cohesin’s α-kleisin subunit Rec8 along 
chromosome arms, but not at centromeres, to 
allow the segregation of recombined homo-
logs to opposite poles. These segregating 
chromosomes are thus composed of two chro-
matids that are only associated at their centro-
meres. The protected cohesin complexes at 
centromeres are then cleaved by a new round 
of separase activity during the metaphase ii/
anaphase ii transition (ref. 1).
During recent years it has been demon-
strated that centromeric cohesin complexes 
are protected against degradation by sepa-
rase during anaphase i by a complex formed 
by shugoshin (Sgo)/MEi-S332 family members 
and a phosphatase 2A (PP2A) that is recruited 
to centromeres (ref. 2 and 3). Different experi-
ments in yeast have revealed that the phos-
phorylation of Rec8 enhances its cleavability 
by separase during  meiosis,4 as occurs with 
its paralog Rad21/Scc1 during mitosis.5 in this 
sense it has been shown that the Polo-like 
kinase phosphorylates Rad21/Scc1 in both 
yeast5 and vertebrate mitotic cells (ref. 6). 
Although it has been suggested that Polo-like 
kinase could also phosphorylate Rec8 dur-
ing yeast meiosis (ref. 4), the identity of the 
kinase(s) responsible for its phosphorylation 
and then promoting its cleavage by separase 
remained to be determined.
in a previous issue of Cell Cycle, Rumpf et al. 
reports that in fission yeast Casein kinase 1δ/ε 
isoforms (CK1δ/ε) are required for Rec8 phos-
phorylation and then for its efficient removal 
during meiosis i.7 The authors first tried to 
identify the phosphorylated residues of Rec8 
around metaphase i by mass spectrometry. 
They found that up to 17 serine/threonine 
residues appeared phosphorylated along 
Rec8. Thereafter, these residues were mutated 
to alanine (Rec8-17A), which can no longer 
be phosphorylated, to analyze meiotic chro-
mosome segregation. Surprisingly, cells only 
showed a mild non-disjunction phenotype. 
However, when they analyzed chromosome 
segregation in a mutant version of Rec8-17A 
with one of the two separase cleavage sites 
also mutated (Rec8-17A-RD1), chromosome 
segregation was greatly inhibited. Taking into 
account this result the authors suggest that, 
since cleavage of Rec8 by separase at either 
of two cleavage sites is sufficient for Rec8 
degradation, Rec8 phosphorylation is needed 
to allow an accurate chromosome segregation 
during meiosis i.
The authors had previously reported that 
mutants for Hrr25 and Hhp1/Hhp2, the ortho-
logs of CK1δ/ε in budding and fission yeast 
respectively, showed abnormal chromosome 
segregation during meiosis i.8 With this in 
mind, they then investigated whether the in 
vivo phosphorylation of Rec8 was dependent 
on Hhp1 and Hhp2. The results indicated that 
in double mutants for these isoforms Rec8 
was not phosphorylated and high levels of 
Rec8-GFP were present during anaphase i. 
Thus, the authors conclude that Hhp1 and 
Hhp2 are required for the phosphorylation 
of Rec8 and for its efficient cleavage from 
chromosome arms by separase during ana-
phase i. Accordingly, they found that Hhp1 
and Hhp2 tagged with GFP colocalized with 
Rec8. The authors thus suggest that Rec8 is 
phosphorylated by CK1δ/ε from premeiotic 
S-phase up to prophase i all along the chromo-
some arms and also at centromeres. The sub-
sequent recruitment at centromeres of PP2A/
Sgo1 during late prophase i would allow the 
dephosphorylation of centromeric Rec8. Then, 
once separase is activated, it would only cleave 
phosphorylated Rec8 along the arms to trig-
ger the onset of anaphase i (Fig. 1). This same 
model is also supported by two very recent 
reports conducted on fission9 and budding10 
yeast meiosis i. Although the mechanisms 
controlling the phosphorylated state of Rec8 
at the arms and centromeres in yeasts are 
probably evolutionarily conserved, they need 
to be validated in other animal and plant 
model systems.
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Cellular senescence limits the proliferation 
of damaged cells that are at risk of neo-
plastic transformation by imposing an essen-
tially irreversible growth arrest.1 Traditionally, 
senescence has been regarded as a strictly 
intracellular response with the entire signal-
ing taking place within the boundaries of 
the cell. However, recently senescent cells 
have been found to secrete a complex mix-
ture of inflammatory proteins and mediators 
of extracellular matrix remodelling, includ-
ing key components of the Wnt, iGF1, TGFβ, 
plasmin and interleukin signalling cascades.2-4 
Current knowledge suggests that signals from 
these cascades are integrated at the level 
of the plasma membrane to reinforce the 
senescence arrest by autocrine or paracrine 
mechanisms.
The PML protein is an important positive 
regulator of cellular senescence and a tumor 
suppressor commonly lost in human cancer.5 
The protein epitomizes the PML nuclear body 
and is crucially required for its proper assem-
bly. Despite varying PML steady-state levels, 
in most cell types the number and size of 
PML nuclear bodies increases in response to 
soluble factors and cellular stress. Data from 
many groups clearly show that PML nuclear 
bodies are involved in the cellular response to 
DNA damage. One attractive model suggests 
that PML nuclear bodies mark sites of irrepa-
rable DNA lesions and promote signalling to 
checkpoint complexes.
it has been long kown that PML expres-
sion is transcriptionally induced by interfer-
ons in various biological settings.6 However, 
during oncogene-induced senescence, an 
increase in number and size of PML nuclear 
bodies has been described to be caused by 
p53-mediated transcriptional upregulation of 
PML promotes senescence via JAK/STAT signaling
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PML.7 As PML has also been shown to function 
upstream of p53 in inducing senescence and 
apoptosis, these data point to the presence of 
a positive feedback loop. 
in spite of this wealth of information, 
the mechanisms of PML induction during 
cellular senescence and the links between 
senescence and senescence-associated cyto-
kine secretion on the one hand and PML 
expression on the other hand are far from 
being understood. Clarifyingly, in the current 
issue of Cell Cycle, Hubackova and coworkers 
now report that genotoxic drugs that induce 
senescence turn on PML transcription by JAK/
STAT-mediated activation of an interferon 
Stimulated Response Element (iSRE) within 
the PML gene promoter.8 Using a panel of 
different normal and cancer cell lines they 
first show that diverse DNA-damaging drugs 
which are known to induce senescence lead 
to elevation of the number of PML nuclear 
bodies as well as PML transcript and protein 
levels. importantly and in contrast to what 
has been reported earlier, this response could 
be attributed to enhanced PML transcription 
rather than protein stabilisation. As the PML 
gene promoter binds transcription factors 
of the STAT family which are activated by 
cytokine-stimulated JAK kinases, Hubackova 
et al. went on to demonstrate that inhibition 
of JAK signaling via both chemical inhibi-
tors and siRNA prevents PML expression in 
response to genotoxic drugs. Subsequent 
gel shift analyses demonstrated the presence 
of iSRE binding activity in nuclear extracts 
from DNA-damaging drug-treated senes-
cent cells, thereby clearly implicating the 
interferon Stimulated Response Element in 
genotoxic stress-induced PML transcription. 
Experiments with both p53-negative cells and 
a dominant-negative form of p53 showed that 
transcriptional induction of PML in response 
to genotoxic stress was independent of p53.
As previously shown for ionizing radia-
tion already, data presented by Hubackova 
and coworkers confirm that persistent but not 
acute DNA damage foci induced by genotoxic 
drugs colocalize with PML nuclear bodies. 
Since the RecQ helicase BLM was sequestered 
into these foci together with PML bodies, 
these results seem to corroborate earlier sug-
gestions on a repressive effect of PML nuclear 
bodies on DNA repair.
Altogether, the findings reported in this 
study suggest that the expansion of PML 
nuclear bodies after genotoxic stress com-
monly occurs during cellular senescence and 
is attributable to p53-independent transcrip-
tional activation of PML expression. Most 
importantly, PML transcription in response 
to DNA damage is driven by JAK/STAT signal-
ing. Therefore, these findings for the first time 
make the link between senescence-associ-
ated cytokine secretion induced by genotoxic 
drugs and increased PML expression. Whether 
or not enhanced PML nuclear body formation 
during drug-induced senescence serves to 
sustain the senescence arrest of persistently 
damaged cells certainly constitutes a reward-
ing field of further research.
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Cyclin dependent kinases (cdks) are a family 
of serine/threonine kinases whose activity at 
discrete cell cycle stages is required for cells 
to successfully progress into and through the 
cell cycle. As befits enzymes with such crucial 
cellular consequences, the cdks are subjected 
to multiple levels of regulation which include 
acquisition of a cyclin partner, both positive 
and negative phosphorylation, and the actions 
of cyclin dependent kinase inhibitors (cdkis). 
Two members of this kinase family, cdk4 and 
cdk6, are essential for movement into and 
through G1, the cell cycle stage controlled 
by mitogenic signals capable of driving cells 
into the cell cycle. Cdk4 and 6 utilize D-type 
cyclins whose accumulation is likewise regu-
lated by the same external signals. As cycling 
cells complete the growth factor dependent 
phase they commit to S phase by activating 
cdk2 partnered initially with cyclin E. D-type 
cyclin/cdk4/6 and cyclin E/cdk2 promote cycle 
progression in large part by regulating the E2F 
family of transcriptional activators and repres-
sors through phosphorylation of Rb family 
members.
it is not surprising that cell cycle related 
proteins operative during G1 to S phase pro-
gression are found to undergo dysregulation 
during transformation of mammalian cells, 
including B cell lymphomas such as diffuse 
large B cell lymphomas (DLBCL). included 
within the diagnostic category of DLBCL are B 
cell lymphomas that differ in causative genetic 
defects and clinical outcomes.1 These diverse 
lymphomas can be subdivided into two broad 
subsets referred to as activated B-cell-like 
(ABC) DLBCL and germinal centre B-cell-like 
Cyclin independent role for cdk4/6 during B-cell lymphoma survival
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(GCB) DLBCL, and the B cell lymphomas within 
each subset are found to display similar bio-
logical and clinical features. For example, ABC 
DLBCL exhibit chronic signaling through their 
B cell antigen receptors (BCR) while GCB DLBCL 
do not2 and targeting the BCR-induced signal-
ing pathways are found to kill only ABC DLBCL. 
However, a 6p21 amplification responsible for 
elevated accumulation of cyclin D3 is found in 
both DLBCL subsets.3 in a previous issue of Cell 
Cycle, Gumina and colleagues address possible 
functional consequences of cyclin D3 over 
expression in DLBCL. For this purpose they 
select for study the human OCi-Ly18 cell line 
which is derived from a GCB DLBCL. Ly18 cells 
express cyclin D3, cyclin E, cdk2, 4 and 6 and 
are devoid of cyclin D2 and D3 and the cdkis 
p21, p27 and p16. The authors indirectly show 
the presence of active cyclin D3/cdk4 and 6 
and cyclin E/cdk2 complexes by showing that 
Rb is phosphorylated at both cdk4/6 and cdk2 
sites.  The use of siRNA mediated knock down 
demonstrates that survival and expansion of 
Ly18 cells along with full phosphorylation 
of Rb occurs in the absence of either cyclin 
D3 or cyclin E. This result is not surprising 
since mammalian cells are know to prolifer-
ate normally in the absence of either D-type 
cyclins4 or cyclin E5 exemplifying redundan-
cies that serve as protective mechanisms in 
key cell cycle events. More interestingly, they 
find that although single knock downs of 
cdk4, cdk6 or cdk2 are without affect upon 
Ly18 cell viability and expansion, the double 
knock down of cdk4 and cdk6 results in reduc-
tion of proliferation and an accumulation of 
viable cells in the G1 cell cycle stage. The first 
important implication of these findings is the 
identification of cdk4 and 6 as potential thera-
peutic targets for DLBCL and this is particularly 
intriguing based on the availability of inhibi-
tors selective for both cdk4 and cdk6.6 
The data provided by Gumina and col-
leagues open a second, and perhaps even 
more intriguing possibility that cdk4 and cdk6 
exert cyclin independent functions critical for 
Ly18 expansion. The Ly18 cells are able to pro-
liferate normally in the absence of cyclin D3 
(without compensatory expression of either 
cyclin D1 or D2) and in the absence of cyclin 
E or cdk2 as long as they continue to express 
cdk4 and/or cdk6. Roles for cell cycle related 
proteins outside their normal activities are 
being uncovered. Of interest in this context 
is the demonstration that cdk6 enhances the 
transcriptional activity of androgen receptors 
in prostate tumor cells independent of the 
need for a D-type cyclin partner.7 in fact, the 
presence of the cyclin partner inhibits this 
enhancement. is it possible that the reason 
cdk4 and cdk6 represent such an attractive 
therapeutic target in DLBCL is distinct from 
what we appreciate as the traditional role for 
these kinases during G1 progression?
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Lost between the control of initiation of 
eukaryotic transcription and effects of chroma-
tin, how RNA polymerase ii (RNAPii) elongates 
and regulates co-transcriptional process-
ing of nascent transcripts, such as splicing 
and polyadenylation, represented a rather 
neglected field of investigation. This slight was 
due mostly to transcriptional studies in vitro, 
where this regulation was not observed due 
to the loss of negative and positive elonga-
tion factors during the preparation of nuclear 
extracts. Only whole cell extracts established 
the importance of post-initiation events, such 
as RNAPii pausing and release after appropri-
ate signals had been received.1 importantly, 
recent whole genome analyses (WGAs) con-
firmed that this step in transcription is critical 
for the expression of most eukaryotic genes.2
A great deal of what we know about the 
control of elongation of transcription came 
from studies of the human immunodeficiency 
virus (Hiv), which encodes a strong transcrip-
tional transactivator (Tat). Tat not only binds 
an RNA structure, the transactivation response 
(TAR) element, but also affects only the elonga-
tion step of viral transcription. Nevertheless, in 
the absence of Tat, abundant RNAPii is already 
present on the Hiv promoter, which leads to 
the synthesis of short capped but not polyad-
enylated transcripts that contain TAR.3 Stalled 
RNAPii and short transcripts have now been 
found with most inactive and inducible genes 
in a variety of cells and organisms. Studies 
on RNAPii stalling also revealed the negative 
transcription elongation factor (N-TEF), which 
contains the DRB-sensitivity inducing factor 
(DSiF) and negative elongation factor (NELF). 
They arrest RNAPii near the 5’ end of genes.4 
Next, Tat affinity chromatography revealed its 
co-activator, the positive elongation factor b 
(P-TEFb), which is composed of C-type cyclins 
T1 or T2 (CycT1 or CycT2) and the cyclin depen-
dent kinase 9 (Cdk9).5 importantly, Tat recruits 
P-TEFb to TAR, where Cdk9 phosphorylates 
serines at position 2 (Ser2) in the C-terminal 
domain (CTD) of RNAPii and subunits of N-TEF, 
thus converting DSiF to an elongation factor 
and removing NELF from double stranded 
RNA. Although serines at position 5 (Ser5) in 
the CTD had already been phosphorylated 
Transcription elongation takes central stage: The P-TEFb connection
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by Cdk7 in TFiiH, which allows for efficient 
capping of mRNA species, the extensive phos-
phorylation of Ser2 in the 52 heptad repeats 
(ySPTSPS) of the human CTD displaces the 
Mediator complex and recruits the chroma-
tin remodeling, splicing and polyadenylation 
machineries to the now elongating RNAPii.4 
Thus, P-TEFb reverses effects of N-TEF and 
insures proper co-transcriptional processing of 
nascent transcripts. 
P-TEFb itself is regulated tightly in cells 
(Fig. 1).4 it is found in an inactive large com-
plex (LC), where Hexamethylene bisacet-
amide (HMBA) induced proteins (Hexim1 and 
Hexim2, Hexim1/2) inhibit the kinase activity 
of Cdk9 and an active small complex (SC) with 
Bromo domain-containing protein 4 (Brd4), 
the Mixed Lineage Leukemia (MLL) complex 
of elongation factors and/or a plethora of 
transcriptional activators, such as cMyc and 
NFκB.2, 4, 6 Hexim proteins only inactivate P-TEFb 
when bound to 7SK snRNA, an abundant non-
coding product of RNAPiii. Ratios between 
inactive and active P-TEFb as well as levels of 
these C-type cyclins affect the state of prolifer-
ation and differentiation of cells. For example, 
HMBA terminally differentiates leukemic cells 
by increasing the synthesis of Hexim pro-
teins, which inhibit P-TEFb. 7SK snRNA is itself 
capped by methylphosphate capping enzyme 
(MePCE) on its 5’ end and stabilized by La 
related protein 7 (LaRP7) on its 3’ end.4 Without 
these proteins, 7SK snRNA is degraded rapidly 
and active P-TEFb is released in cells. Thus, it is 
Figure 1. P-TEFb and transcriptional elongation. P-TEFb (CycT1:Cdk9) is found in an inactive 
large complex (LC) and active small complexes (SC). LC contains two copies of Hexim1/2. 
MePCE and LaRP7 stabilize 7SK snRNA. Stress, Uv light and other stimuli release the active P-
TEFb (SC) from the LC (1). P-TEFb is then recruited to transcription units via activators such as 
NF-κB and cMyc, Brd4 as well as MLL complexes (2). initiating RNAPii stalls and is phosphory-
lated on Ser5, which facilitates capping. P-TEFb then phosphorylates Ser2 in the CTD as well 
as subunits of NELF and DSiF (3). NELF dissociates from RNAPii and DSiF is converted to an 
elongation factor (4). Highly phosphorylated RNAPii elongates with the chromatin remodel-
ing, splicing and polyadenylation machineries and co-transcriptional processing ensues. 
P-TEFb can also travel with RNAPii.
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not surprising that many cervical, gastric 
and breast cancers disregulate the LaRP7 
gene.7 
Why would increased levels of P-TEFb 
lead to malignant transformation? First of all, 
effects of cMyc and NFκB will be amplified.2 
Levels of cell cycle cyclins, such as CycD1 
will increase, since flavopiridol, an inhibitor 
of P-TEFb, has the opposite effect.8 Next, a 
number of anti-apoptotic and early response 
genes will be induced, some of which code for 
potent growth factors.9 Finally, as suggested 
by this report, the Rb/E2F1 pathway will be 
disregulated. Further WGAs will reveal addi-
tional targets. importantly, inhibiting P-TEFb 
should be considered for future therapies 
of cancer, inflammation and hypertrophic 
diseases. 
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The mTORC1 complex contains mTOR kinase 
and is known to control the rate of protein 
synthesis and thereby cell growth in response 
to nutrient availability.1 it uses several mecha-
nisms to achieve this, the best understood of 
which is the direct phosphorylation of 4E-BP, 
an inhibitor of translation initiation.1 Levels 
of tRNA can be rate-limiting for translation in 
some cell types.2 Control of tRNA expression 
might therefore provide an additional potent 
means to influence protein production.
A flurry of recent papers have established 
that tRNA synthesis in mammalian cells is 
controlled by mTORC1.3-6 This is consistent 
with previous working establishing similar 
control of tRNA gene transcription by TORC1 
in budding yeast.7 in both humans and yeast, 
control is mediated through a repressor called 
Maf1 that binds and inhibits RNA polymerase 
iii, the enzyme responsible for transcribing 
tRNA genes. inactivation of Maf1 by mTORC1 
may be direct, as recombinant Maf1 can be 
phosphorylated in vitro by a recombinant 
fragment of mTOR or the mTORC1 complex 
immunoprecipitated from human cells.5,6 One 
of the target residues is serine 75, a site that 
is phosphorylated in vivo and which controls 
Maf1 function.4-6
inactivation of the transcriptional repres-
sor Maf1 by mTORC1 is strongly reminiscent 
of its effect on the translational repressor 
4E-BP, which binds and inhibits the mRNA cap-
binding factor eiF4E.1 The analogy is strength-
ened by the fact that in both cases mTORC1 
is localised to a nucleic acid template, allow-
ing precise targeting to its substrate. Thus, 
mTORC1 is recruited to certain transcripts by 
the sequence-specific mRNA-binding factor 
A feedback loop between mTOR and tRNA expression?
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SF2/ASF, allowing it to act directly to release 
4E-BP.8 Similarly, mTORC1 is detected at tRNA 
and 5S rRNA gene promoters, which it can 
free from Maf1-mediated repression.3-5 it can 
be targeted to these sites by the DNA-binding 
transcription factor TFiiiC, which contains a 
TOR signalling (TOS) motif like the one pres-
ent in 4E-BPs.5 Point mutation of the TOS 
motif in TFiiiC compromises its association 
with mTORC1 in vivo.5 
Huynh et al. have found evidence to suggest 
that mTORC1 responds to tRNA.9 This raises the 
possibility of a feedback loop between tRNA 
levels and mTORC1 activity (Fig. 1). Their dis-
covery is based on the effect of RNAi-mediated 
depletion of Xpo-t, a karyopherin responsible 
for export of tRNA from the nucleus into the 
cytoplasm. When Xpo-t levels are reduced 
in human fibroblasts, a decrease is observed 
in the phosphorylation of well-characterised 
mTORC1 target sites, including phosphoaccep-
tors in 4E-BP.9 This correlates with the expected 
nuclear accumulation of tRNA.9 On the basis 
of this observation, the authors propose a 
model in which tRNA contributes to homeo-
stasis by modulating signaling pathways that 
protect against nutrient limitation. indeed, 
they also found that Xpo-t depletion from 
fibroblasts promotes autophagy, a key sur-
vival mechanism under starvation conditions.9 
This response may be ancient, as autophago-
somes accumulate in a yeast strain deleted 
for the tRNA-transporting karyopherin LOS1.9 
A caveat to this appealing model is that the 
authors have manipulated the karyopherins, 
rather than tRNAs themselves; the possibility 
therefore remains that the observed responses 
are triggered by some tRNA-unrelated function 
of the karyopherins, that may yet be undiscov-
ered. Nevertheless, the hypothesis that cells 
Figure 1. Model in which tRNA expression influences the activity of mTORC1 through some 
undefined mechanism. in turn, mTORC1 can stimulate synthesis of tRNA by phosphorylating 
and inactivating Maf1, a repressor of RNA polymerase iii. This may occur in the nucleus, where 
mTORC1 associates with TFiiiC, a transcription factor that binds to tRNA gene promoters. 
indeed, mTORC1 can be crosslinked in vivo to tRNA genes.
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Cyclin-dependent kinases (Cdks) are a family 
of serine/threonine protein kinases involved 
in cell cycle control and/or regulation of tran-
scription. The enzymatic activity of the Cdks 
depends on their binding to a regulatory 
cyclin subunit. Until now, current evidence 
had indicated that positive transcription elon-
gation factor b (P-TEFb), a heterodimer con-
sisting of Cdk9 and one of the C-type cyclins 
(T1, T2a, T2b, or K), does not directly regulate 
the cell cycle.1 indeed, the main function of 
Cdk9 consists of regulating transcription via 
phosphorylation of the RNA polymerase ii 
(polii) carboxyl terminal domain.2 
in this issue of Cell Cycle, an article by 
Moiola et al. demonstrates for the first time 
that cyclin T1, one of the most recently 
described members of the family of cyclins,3 
induces the transformation of NiH 3T3 cells in 
P-TEFb joins the family of cdks in oncology, promotes  
cell growth of cancer cells
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vitro and tumorigenesis in vivo. Their studies 
also suggest that P-TEFb induces NiH 3T3 cell 
proliferation by CDK4-mediated Rb phosphor-
ylation. Thus, these findings identify cyclin T as 
an oncogene and suggest that Cyclin T plays a 
role in controlling the cell cycle, probably via 
the Rb/E2F1 pathway, previously unknown 
roles of P-TEFb. 
Of note, Moiola and colleagues also report 
that PTEFb is overexpressed in human head 
and neck tumors as compared with its expres-
sion in normal tissue, thus implicating PTEFb 
for the first time in the pathogenesis of head 
and neck cancers. Head and neck cancers 
account for about 3% of malignancies in 
the United States,4 and although advances 
in therapy in the last decade have provided 
better local control of advanced cancers, the 
improvements in overall survival have been 
modest.5 in conjunction with early detection, 
the identification and use of biomarkers of 
therapy response and disease progression may 
facilitate disease management. Specifically, 
these biomarkers could guide in the identi-
fication of precancers that could progress to 
invasive lesions or those that could respond 
differently to various therapies. The report by 
Moiola et al. in this issue thus introduces a new 
player that could be used to bring us closer to 
individualized disease management for head 
and neck cancers.
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respond to tRNA as well as to amino acids 
is exciting and attractive. The TORC1 path-
way is ideal to integrate inputs from such 
signals. inappropriate levels or localization 
of tRNA might in this way influence both 
the activity and production of the transla-
tion apparatus, including synthesis of tRNAs 
themselves. Feedback control of tRNA produc-
tion would be especially important in cells in 
which the rate of translation is limited by tRNA 
availability.2
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